Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan H Fox

Showing results (81-90 of 178) with videos related to

Pageof 18
Sort By:
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2010
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primatesTom H Johnston, Susan H Fox, Matthew J Piggott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2006
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseJordi Gomez-Ramirez, Tom H Johnston, Naomi P Visanji, et al.
Current Neurology and Neuroscience Reports|January 20, 2017
Integrating Patient Concerns into Parkinson's Disease ManagementShen-Yang Lim, Ai Huey Tan, Susan H Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 17, 2010
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseTom H Johnston, Susan H Fox, Matthew J McIldowie, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|January 16, 2018
Botulinum Toxin Type A for Pain in Advanced Parkinson's DiseaseVeronica Bruno, Maria Eliza Freitas, Deborah Mancini, et al.
JAMA Neurology|September 23, 2024
Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear PalsyIvan Martinez-Valbuena, M Carmela Tartaglia, Susan H Fox, et al.
Neurobiology of Aging|November 6, 2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neurobiology of Disease|January 3, 2009
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's diseaseNaomi P Visanji, Susan H Fox, Tom Johnston, et al.
Journal of Neurology|December 14, 2004
A 10 year retrospective audit of long-term apomorphine use in Parkinson's diseaseHilary L Tyne, Jan Parsons, Ann Sinnott, et al.
Pageof 18

Showing results (81-90 of 178) with videos related to

Sort By:
Pageof 18
Current Neurology and Neuroscience Reports|June 12, 2009
New insights into the organization of the basal gangliaJames B Koprich, Tom H Johnston, Philippe Huot, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2010
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primatesTom H Johnston, Susan H Fox, Matthew J Piggott, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 15, 2006
Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseJordi Gomez-Ramirez, Tom H Johnston, Naomi P Visanji, et al.
Current Neurology and Neuroscience Reports|January 20, 2017
Integrating Patient Concerns into Parkinson's Disease ManagementShen-Yang Lim, Ai Huey Tan, Susan H Fox, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 17, 2010
Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's diseaseTom H Johnston, Susan H Fox, Matthew J McIldowie, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|January 16, 2018
Botulinum Toxin Type A for Pain in Advanced Parkinson's DiseaseVeronica Bruno, Maria Eliza Freitas, Deborah Mancini, et al.
JAMA Neurology|September 23, 2024
Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear PalsyIvan Martinez-Valbuena, M Carmela Tartaglia, Susan H Fox, et al.
Neurobiology of Aging|November 6, 2010
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaquePhilippe Huot, Tom H Johnston, James B Koprich, et al.
Neurobiology of Disease|January 3, 2009
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's diseaseNaomi P Visanji, Susan H Fox, Tom Johnston, et al.
Journal of Neurology|December 14, 2004
A 10 year retrospective audit of long-term apomorphine use in Parkinson's diseaseHilary L Tyne, Jan Parsons, Ann Sinnott, et al.
Pageof 18